期刊文献+

彩色多普勒超声及超声造影在乳腺癌新辅助化疗疗效评估中的价值 被引量:8

The value of color Doppler ultrasound and contrast-enhanced ultrasound in assessment of neoadjuvant chemotherapy in breast cancer
下载PDF
导出
摘要 目的探讨彩色多普勒超声及超声造影对乳腺癌新辅助化疗(neoadjuvant chemotherapy,NAC)疗效评估中的应用价值。方法选取2014年1月—2015年6月收治的行NAC乳腺癌患者60例,分别于NAC前和NAC后应用彩色多普勒超声记录病灶大小、血流分级、血流阻力指数等指标;对其中26例行超声造影检查患者记录造影相关参数,包括造影剂到达肿瘤的时间、达峰时间及峰值强度。根据NAC前、后各项指标变化情况评估NAC疗效。结果 NAC后病灶最大径、形态、边界、周边晕带、内部回声变化、血流分级及血流阻力指数均较NAC前差异有统计学意义(P<0.05)。NAC后造影相关参数到达肿瘤的时间、达峰时间及峰值强度均较NAC前有明显变化,差异有统计学意义(P<0.05)。结论超声造影可以通过检测乳腺癌NAC前、后各项指标变化情况,准确评估NAC疗效。 Objective To investigate the value of color Doppler ultrasound and contrast-enhanced ultrasound evaluation of the efficacy of neoadjuvant chemotherapy( neoadjuvant chemotherapy,NAC) in breast cancer. Methods This study included 60 breast cancer patients who received NAC and surgical treatment between January 2014 to June 2015. Tumor sizes,blood flow grading,resistance index( RI) and other related indicators were recorded before and after chemotherapy using color Doppler ultrasound. Of which 26 patients were examined by contrast-enhanced ultrasound and recorded relevant parameters,which including arrival time,time to peak and peak intensity,the efficacy of NAC was assessed according to the change of before and after chemotherapy. Results The maximum lesion diameter,shape,border,surrounding halo zone,change internal echo,blood flow grading and RI values after NAC had significant changes than before( P < 0. 05). The AT,TTP and PI after NAC had significant difference than before( P < 0. 05). Conclusion Contrast-enhanced ultrasound can detect changes in the indicators NAC before and after chemotherapy in breast cancer cases and accurately assess the efficacy of NAC.
出处 《转化医学杂志》 2016年第2期74-77,共4页 Translational Medicine Journal
基金 内蒙古自然科学基金面上项目(2015MS08110)
关键词 乳腺癌 新辅助化疗 彩色多普勒超声 超声造影 Breast cancer Neoadjuvant chemotherapy(NAC) Color Doppler ultrasound Contrast-enhanced ultrasound
  • 相关文献

参考文献4

二级参考文献28

  • 1Wolmark N,Wang J,Manounas E,et al.Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J].J Natl Cancer Inst Monogr,2001,(30):96-102.
  • 2Kaufmann M,Hortobagyi GN,Goldhirsch A,et al.Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer:an update[J].J Clin Oncol,2006,24(12):1940-1949.
  • 3Shimizu C,Ando M,Kouno T,et al.Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer[J].Jpn J Clin Oncol,2007,37(1):1-8.
  • 4Bear HD,Anderson S,Smith RE,et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2006,24(13):2019-2027.
  • 5Trudeau M,Sinclair SE,Clemons M,et al.Neoadjuvant taxanes in the treatment of non-metastatic breast cancer:a systematic review[J].Cancer Treat Rev,2005,31 (4):283-302.
  • 6Estevez LG,Gradishar WJ.Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer[J].Clin Cancer Res,2004,10(10):3249-3261.
  • 7Smith IC,Heys SD,Hutcheon AW,et al.Neoadjuvant chemotherapy in breast cancer:significantly enhanced response with docetaxel[J].J Clin Oncol,2002,20(6):1456-1466.
  • 8von Minckwitz G,Blohmer JU,Raab G,et al.In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer:the GEPARTRIO pilot study[J].Ann Oncol,2005,16(9):1559-1560.
  • 9Buzdar AU,Ibrahim NK,Francis D,et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J].J Clin Oncol,2005,23(16):3676-3685.
  • 10Rouzier R,Perou CM,Symmans WF,et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J].Clin Cancer Res,2005,11(16):5678-5685.

共引文献66

同被引文献68

引证文献8

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部